These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36685947)

  • 1. A novel cuproptosis-related lncRNA signature predicts prognosis and therapeutic response in bladder cancer.
    Cai J; Xie H; Yan Y; Huang Z; Tang P; Cao X; Wang Z; Yang C; Wen J; Tan M; Zhang F; Shen B
    Front Genet; 2022; 13():1082691. PubMed ID: 36685947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
    Wang F; Lin H; Su Q; Li C
    World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
    Zhang X; Ye Z; Xiao G; He T
    Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma.
    Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer.
    Pan Y; Zhang Q; Zhang H; Kong F
    Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma.
    Xu M; Mu J; Wang J; Zhou Q; Wang J
    Front Oncol; 2022; 12():961213. PubMed ID: 35965536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for acute myeloid leukemia.
    Li P; Li J; Wen F; Cao Y; Luo Z; Zuo J; Wu F; Li Z; Li W; Wang F
    Front Oncol; 2022; 12():966920. PubMed ID: 36276132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of cuproptosis-related lncRNAs in the prognosis and therapy response of patients with bladder cancer.
    Li D; Wu X; Fan X; Cheng C; Li D; Zhang W
    Ann Transl Med; 2022 Nov; 10(22):1232. PubMed ID: 36544685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer.
    Bai Y; Zhang Q; Liu F; Quan J
    Front Immunol; 2022; 13():1027449. PubMed ID: 36451815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive analysis of cuproptosis-related lncRNAs signature to predict prognosis in bladder urothelial carcinoma.
    Zhu S; Li H; Fan Y; Tang C
    BMC Urol; 2023 Jul; 23(1):124. PubMed ID: 37479989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis of cuproptosis-related long non-coding RNA signature and personalized therapeutic strategy of breast cancer patients.
    Guo Q; Qiu P; Pan K; Lin J
    Front Oncol; 2022; 12():1081089. PubMed ID: 36620596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel cuproptosis-related lncRNA signature to predict prognosis and immune landscape of lung adenocarcinoma.
    Wang X; Jing H; Li H
    Transl Lung Cancer Res; 2023 Feb; 12(2):230-246. PubMed ID: 36895935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction and validation of cuproptosis-related lncRNA prediction signature for bladder cancer and immune infiltration analysis.
    Li H; Jiang H; Huang Z; Chen Z; Chen N
    Aging (Albany NY); 2023 Aug; 15(16):8325-8344. PubMed ID: 37616061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prognostic cuproptosis-related lncRNA predictive signature for bladder cancer patients.
    Jiang S; Zhang J; Fan Q; Li Z; Dou R; Lin Z; Chen Z; Xu Y; Huang Z; Lan J; Lin W; Xu S; Gao X; Li M
    Hum Cell; 2023 Mar; 36(2):798-811. PubMed ID: 36709471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cuproptosis-Associated lncRNA Establishes New Prognostic Profile and Predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma.
    Xu S; Liu D; Chang T; Wen X; Ma S; Sun G; Wang L; Chen S; Xu Y; Zhang H
    Front Genet; 2022; 13():938259. PubMed ID: 35910212
    [No Abstract]   [Full Text] [Related]  

  • 16. Identification of novel cuproptosis-related lncRNA signatures to predict the prognosis and immune microenvironment of breast cancer patients.
    Jiang ZR; Yang LH; Jin LZ; Yi LM; Bing PP; Zhou J; Yang JS
    Front Oncol; 2022; 12():988680. PubMed ID: 36203428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction and validation of a novel cuproptosis-related long noncoding RNA signature for predicting the outcome of prostate cancer.
    Jiang S; Li Z; Dou R; Lin Z; Zhang J; Zhang W; Chen Z; Shen X; Ji J; Qu M; Wang Y; Li M; Gao X
    Front Genet; 2022; 13():976850. PubMed ID: 36561322
    [No Abstract]   [Full Text] [Related]  

  • 18. Identification of cuproptosis-related long noncoding RNA signature for predicting prognosis and immunotherapy response in bladder cancer.
    Huang G; Huang Y; Zhang C; Jiang Y; Ye Z; He C; Yu F; Chen Z; Xi X
    Sci Rep; 2022 Dec; 12(1):21386. PubMed ID: 36496537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and validation of a novel cuproptosis-related lncRNA signature for prognosis and immunotherapy of head and neck squamous cell carcinoma.
    Xu QS; Shen ZZ; Yuan LQ
    Front Cell Dev Biol; 2022; 10():968590. PubMed ID: 36467424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cuproptosis-related long noncoding RNAs predicts overall survival and reveal immune microenvironment of bladder cancer.
    Wang H; Lv Z; Xia H; Tang R; Liu M; Wang J; Wang J
    Heliyon; 2023 Dec; 9(12):e21153. PubMed ID: 38094043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.